Pliant Therapeutics Inc Ordinary Shares PLRX
News
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Respiratory Society International Congress 2024
Korro Announces Addition of Industry Veteran Katharine Knobil to and Resignation of David Lucchino From Its Board of Directors
Pliant Therapeutics to Participate in Upcoming Investor Events
Pliant Therapeutics Announces Four Upcoming Presentations at the European Respiratory Society International Congress 2024
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
Pliant Therapeutics to Participate in the Canaccord Genuity 44th Annual Growth Conference
Pliant Therapeutics Announces Positive Long-Term Data from the INTEGRIS-PSC Phase 2a Trial Demonstrating Bexotegrast was Well Tolerated at 320 mg with Continued Antifibrotic and Anti-Cholestatic Activity Displayed Across Multiple Measures
Amazon and JPMorgan stocks fall, Rivian and DraftKings shares rally, and other stocks on the move
Pliant Therapeutics shares surge as liver-disease treatment shows promise in clinical trial